Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Coherus Biosciences Inc chart...

About the Company

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

CEO

Dennis Lanfear

Exchange

NASDAQ

Website

https://www.coherus.com/

$35M

Total Revenue

377

Employees

$249M

Market Capitalization

-0.91

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CHRS News

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

2d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, ...

Why Coherus Biosciences Stock Tumbled on Thursday

on MSN ago, source:

The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and ...

Coherus gains as oncology focus leads to job cuts

on MSN ago, source:

Coherus BioSciences (CHRS) stock gains as the company plans to cut 30% of its workforce as it focuses on cancer drugs. Read ...

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs

5d ago, source: FiercePharma

About a year after launching a prior round of layoffs, Coherus BioSciences is again reducing its head count, this time by 30% ...

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

5d ago, source:

Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter ...

Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating

4d ago, source:

In a report released yesterday, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Coherus Biosciences (CHRS – Research ...

Sandoz acquires retinal disease drug business from Coherus, to build biosimilar and ophthalmology leadership in US market

14d ago, source: The Financial Express on MSN

Sandoz and Coherus entered into an agreement in January 2024 through which Sandoz agreed to acquire the full CIMERLI business for an upfront cash purchase price of USD 170 million.

Sandoz completes acquisition of Cimerli business from Coherus BioSciences

14d ago, source: Pharmabiz

Sandoz completes acquisition of Cimerli business from Coherus BioSciences: Basel Tuesday, March 5, 2024, 10:00 Hrs [IST] Sandoz, the global leader in generic and biosimilar medici ...

Coherus Biosciences Inc (NASDAQ:CHRS) Slides -3.10 Percent In Recent Trade, What Can We Expect Next?

21d ago, source:

Looking further, we note the current price level is 2.59% off its SMA20 and 0.32% from its 50-day simple moving average. The RSI (14) is pointing at 49.75 while the volatility over the past week is ...

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

14d ago, source: Asia One

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market ...

Funding wrap: Over $100M raised by startups tackling baby gut health, autonomous driving and more

13d ago, source:

On March 5, Tiny Health announced it raised an $8.5 million series A round led by Spero Ventures, a California-based firm ...

Sandoz concludes acquisition of Cimerli business from Coherus BioSciences

14d ago, source: Daily

CIMERLI is indicated for the treatment of certain retinal diseases that, if left untreated, can cause vision loss, which ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...